Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the development of ateganosine (THIO), a first-in-class telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). News about MAIA often centers on clinical milestones, regulatory designations, and financing activities that support its oncology programs.
Investors and observers following MAIA’s news can expect regular updates on its Phase 2 THIO-101 and Phase 3 THIO-104 trials. These items include announcements of first patient dosing, expansion into new countries, enrollment progress, and presentations of trial-in-progress posters at major conferences such as the Society for Immunotherapy of Cancer (SITC), the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and the European Society for Medical Oncology (ESMO) Congress.
MAIA’s press releases, many of which are furnished via Form 8-K filings, also highlight regulatory developments such as the U.S. FDA Fast Track designation for ateganosine in NSCLC and Orphan Drug Designations in additional tumor types. Another recurring theme in the company’s news is insider activity: open-market share purchases by the CEO and directors, and participation by board members in private placement financings, which the company frames as signals of confidence in the ateganosine platform.
On this news page, readers can review MAIA’s announcements related to clinical data signals, trial design details, international site activations, and capital raises that fund key study steps. For those tracking the progress of telomere-targeting approaches in oncology and the later-line NSCLC treatment landscape, MAIA’s news provides an ongoing record of how its investigational therapy is advancing through mid- to late-stage clinical development.
MAIA Biotechnology announced plans to initiate its second Phase 2 trial, THIO-102, for evaluating its telomere-targeting agent THIO in combination with checkpoint inhibitors such as pembrolizumab and atezolizumab. This trial will target multiple cancer types, including small cell lung cancer and liver cancer. THIO has already received two Orphan Drug Designations from the FDA, reflecting its significant potential. Positive preclinical results indicate that THIO enhances the efficacy of pembrolizumab and can convert 'cold' tumors into responsive ones. The trial aims for accelerated approvals across several indications, potentially numbering over ten.
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced advancements in its Telomere-Targeting Molecule Program, known as Project T3, aimed at developing novel anti-cancer agents. The company has identified two lead candidates, MAIA-2021-20 and MAIA-2022-12, for further preclinical evaluation, with potential progression to human clinical trials. The research showed promising anti-cancer activity in various models and demonstrated the compounds' ability to induce tumor cell death. Additionally, a provisional patent for these new molecules was filed in Q4 2022, marking a significant milestone for MAIA in its oncology-focused initiatives.
MAIA Biotechnology, Inc. (NYSE American: MAIA) will participate in four investor conferences in January and February 2023. Highlighted events include the Biotech Showcase in San Francisco (January 9-11), where they will present on January 9. Additional conferences are the JPM One-on-One Partnering (January 9-12), the Sidoti Micro-Cap Virtual Conference (January 18-19), and the BIO CEO & Investor Conference in New York City (February 6-7). MAIA is currently enrolling patients in the Part A safety lead-arm of the THIO-101 Phase 2 clinical trial for advanced Non-Small Cell Lung Cancer.
MAIA Biotechnology, Inc. announced the completion of a pre-Investigational New Drug (pre-IND) meeting with the FDA regarding the THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). The FDA provided positive feedback on MAIA's manufacturing and clinical development plan. MAIA plans to file its U.S. IND in the first half of 2023 and initiate patient enrollment in the second half. The THIO-101 trial aims to evaluate the safety and efficacy of THIO when administered before Regeneron’s anti-PD1 therapy, Libtayo®, targeting patients with advanced NSCLC.
MAIA Biotechnology has received regulatory approval to initiate the THIO-101 Phase 2 clinical trial in Hungary, Poland, and Bulgaria, expanding its patient access for the investigation of THIO in non-small cell lung cancer (NSCLC). The trial aims to evaluate THIO's capacity to enhance immune response when paired with Regeneron's anti-PD1 therapy, Libtayo (cemiplimab). The main focus is on safety, tolerability, and efficacy in patients who have previously relapsed after checkpoint inhibitor treatments. The trial is a significant step for MAIA in advancing cancer therapies.
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced plans for additional insider investments by its CEO, Vlad Vitoc, and Board Member, Stan Smith, Ph.D., under Rule 10b5-1 trading plans. These plans allow purchases of common stock under regulated conditions. Vitoc expressed confidence that MAIA's valuation does not reflect its growth potential, highlighting innovative assets in oncology. Smith reiterated his commitment, noting the company's revolutionary approach to cancer treatment. MAIA focuses on developing first-in-class oncology drugs, particularly a telomere targeting agent for NSCLC.
MAIA Biotechnology announced promising results for its lead drug candidate, THIO, from a pre-clinical study on hepatocellular carcinoma (HCC) presented at the SITC 37th Annual Meeting. The study showed that THIO enhances the efficacy of immune checkpoint inhibitors by directly killing cancer cells and stimulating an anti-tumor immune response. Notably, THIO, which received Orphan Drug Designation from the FDA, exhibited complete responses in several HCC models with no dose-limiting toxicities. MAIA emphasizes THIO's potential to address the growing need for effective HCC treatments.
MAIA Biotechnology, Inc. reported financial results for Q3 2022, highlighting a net loss of approximately $3.9 million, an improvement from $5.2 million in Q3 2021. The company’s cash position increased to about $14.1 million, sufficient for 12 months of operations. Key developments include an oral presentation on the THIO platform and ongoing THIO-101 trial disclosures. MAIA was added to the Longevity Stock Index, emphasizing its focus on cancer immunotherapies targeting telomeres.
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced its participation in the ThinkEquity Conference on October 26 at 3:00 pm ET. The management team will present and host investor meetings during the event. A webcast of the presentation will be accessible via the Company's website, with a replay available for 30 days post-event. MAIA focuses on developing first-in-class oncology drugs, particularly THIO for NSCLC.
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced it will present study results of the anticancer agent 6-thio-dG (THIO) for hepatocellular carcinoma (HCC) at the EORTC-NCI-AACR Symposium, occurring in Barcelona, Spain from Oct. 26-28, 2022. The data indicates THIO's high anticancer activity and improved tumor response when used sequentially with cemiplimab in HCC models. The U.S. FDA granted THIO Orphan Drug Designation for HCC earlier in 2022, a disease projected to exceed 1 million global cases by 2025.
Presentation is scheduled for Oct. 26 at 12:00pm CEST.